Ublituximab
TG1101-RMS201E
Phase 2 mab completed
Quick answer
Ublituximab for Relapsing Remitting Multiple Sclerosis is a Phase 2 program (mab) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TG THERAPEUTICS, INC.
- Indication
- Relapsing Remitting Multiple Sclerosis
- Phase
- Phase 2
- Modality
- mab
- Status
- completed